<em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development
<i>Pseudomonas aeruginosa</i> is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, <i>P. aeruginosa</i> causes a range of complicated acute and chronic infections in immunocompromised indi...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/7/1100 |
| _version_ | 1797433033174810624 |
|---|---|
| author | Matthew Killough Aoife Maria Rodgers Rebecca Jo Ingram |
| author_facet | Matthew Killough Aoife Maria Rodgers Rebecca Jo Ingram |
| author_sort | Matthew Killough |
| collection | DOAJ |
| description | <i>Pseudomonas aeruginosa</i> is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, <i>P. aeruginosa</i> causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of <i>P. aeruginosa</i> clinical infections and its major important virulence factors. |
| first_indexed | 2024-03-09T10:10:17Z |
| format | Article |
| id | doaj.art-3f0e9179cc0847c68292729ad8b759a5 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T10:10:17Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-3f0e9179cc0847c68292729ad8b759a52023-12-01T22:46:23ZengMDPI AGVaccines2076-393X2022-07-01107110010.3390/vaccines10071100<em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine DevelopmentMatthew Killough0Aoife Maria Rodgers1Rebecca Jo Ingram2Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT7 1NN, UKDepartment of Biology, The Kathleen Lonsdale Institute for Human Health Research, Maynooth University, R51 A021 Maynooth, IrelandWellcome-Wolfson Institute for Experimental Medicine, Queen’s University Belfast, Belfast BT7 1NN, UK<i>Pseudomonas aeruginosa</i> is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, <i>P. aeruginosa</i> causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of <i>P. aeruginosa</i> clinical infections and its major important virulence factors.https://www.mdpi.com/2076-393X/10/7/1100<i>Pseudomonas aeruginosa</i>vaccinescystic fibrosisantibiotic resistancemucosal immunity |
| spellingShingle | Matthew Killough Aoife Maria Rodgers Rebecca Jo Ingram <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development Vaccines <i>Pseudomonas aeruginosa</i> vaccines cystic fibrosis antibiotic resistance mucosal immunity |
| title | <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development |
| title_full | <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development |
| title_fullStr | <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development |
| title_full_unstemmed | <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development |
| title_short | <em>Pseudomonas aeruginosa</em>: Recent Advances in Vaccine Development |
| title_sort | em pseudomonas aeruginosa em recent advances in vaccine development |
| topic | <i>Pseudomonas aeruginosa</i> vaccines cystic fibrosis antibiotic resistance mucosal immunity |
| url | https://www.mdpi.com/2076-393X/10/7/1100 |
| work_keys_str_mv | AT matthewkillough empseudomonasaeruginosaemrecentadvancesinvaccinedevelopment AT aoifemariarodgers empseudomonasaeruginosaemrecentadvancesinvaccinedevelopment AT rebeccajoingram empseudomonasaeruginosaemrecentadvancesinvaccinedevelopment |